DCAT Week 2025: Optimizing Drug Development
BioPharm International® spoke with Helen Baker, director of Formulation Design at Quotient Sciences to find out how drug development can be optimized to ensure a more secure supply chain.
Using a fully integrated service provider can help optimize drug development, says Helen Baker, director of Formulation Design at Quotient Sciences. Having clinical, late-stage, and regulatory processes under one umbrella can also help secure the supply chain.
“A huge advantage of [having services under one umbrella] is that you cut out the white space that you often see between services as you move between them, as you go through the development process,” Baker says. “And this reduces the risk. It reduces the time, and it reduces the cost. [It] also ensures that there's a continuity of service, [and] your quality is always going to be the same. There's a single product manager … managing everything from start to finish. And it just simplifies the whole process, reduces that risk [of] what we already know is a very lengthy, costly and risky development process.”
Quotient Sciences showcased its Translational Pharmaceutics platform at DCAT Week 2025, which was held in New York City from March 17–20.
Click the video above to watch the interview.
About the speaker
Helen Baker is director of Formulation Design, Quotient Sciences
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
